Ads
related to: nonalcoholic steatohepatitis treatment- About NASH
Learn more about the consequences
of NASH and patient management.
- NASH With Fibrosis
Learn about the basics of NASH
on the official HCP website.
- About NASH
Search results
Results from the WOW.Com Content Network
Nonalcoholic steatohepatitis (NASH). With this type of fatty liver disease, you’ll have fat in your liver, inflammation, and liver cell damage. This can lead to cirrhosis (liver scarring) and ...
Metabolic dysfunction–associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), [a] is a type of chronic liver disease.This condition is diagnosed when there is excessive fat build-up in the liver (hepatic steatosis), and at least one metabolic risk factor.
Steatohepatitis is a type of fatty liver disease, characterized by inflammation of the liver with concurrent fat accumulation in liver. Mere deposition of fat in the liver is termed steatosis , and together these constitute fatty liver changes.
In the study Children of the 90s, 2.5% born in 1991 and 1992 were found by ultrasound at the age of 18 to have non-alcoholic fatty liver disease; five years later transient elastography found over 20% to have the fatty deposits on the liver, indicating non-alcoholic fatty liver disease; half of those were classified as severe. The scans also ...
Resmetirom has been seen as a promising candidate for the treatment of nonalcoholic steatohepatitis (NASH) since its late-stage study in December helped reduce liver scarring or fibrosis in ...
Resmetirom, sold under the brand name Rezdiffra, is a medication used for the treatment of noncirrhotic nonalcoholic steatohepatitis. [1] It is a thyroid hormone receptor beta (NR1A2) agonist. [1] The most common side effects include diarrhea and nausea. [2] Resmetirom was approved for medical use in the United States in March 2024.
Aramchol is an investigational drug being developed by Galmed Pharmaceuticals as a first-in-class, potentially disease modifying treatment for nonalcoholic steatohepatitis, or NASH, a more advanced condition of non-alcoholic fatty liver disease. [1] [2] [3] [4]
PXL065 (d-R-pioglitazone) is a drug candidate for the treatment of nonalcoholic steatohepatitis (NASH). [a] It is the deuterium-stabilized (R)-enantiomer of pioglitazone which lacks PPARγ agonist activity and the associated side effects of weight gain and edema. [1]
Ads
related to: nonalcoholic steatohepatitis treatment